Profile Image
Scott Smith Photo
Name
Scott Smith
Degree
M.D.,Ph.D.
FACP
Rank
Professor
Primary Department
Hematology/Oncology
Appointment Request
Request an Appointment
Specialties
Leukemia
Non-Hodgkin's Lymphoma
Refractory Lymphoma
Relapsed Lymphoma
Bone Marrow Disorders
Locations
Cardinal Bernardin Cancer Center
Certifications
American Board of Internal Medicine Subspecialty Hematology
Education
Advanced Degrees
Wayne State University School of Medicine , Detroit , MI , United States
Medical School
Wayne State University School of Medicine
Residencies
Loyola University Medical Center, Internal Medicine: General
Fellowships
Loyola University Medical Center, Hematology/Oncology
Hobbies
Fly Fishing
Mountain Biking
Hiking
Reading
Golf
Publications
Scardina,T. L.; Kang Martinez,E.; Balasubramanian,N.; Fox-Geiman,M.; Smith,S. E.; Parada,J. P.Evaluation of Risk Factors for Clostridium difficile Infection in Hematopoietic Stem Cell Transplant Recipients Pharmacotherapy 2017 ;37(4):420-428
Smith,S. M.; Pitcher,B. N.; Jung,S. H.; Bartlett,N. L.; Wagner-Johnston,N.; Park,S. I.; Richards,K. L.; Cashen,A. F.; Jaslowski,A.; Smith,S. E.; Cheson,B. D.; Hsi,E.; Leonard,J. P.Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials The Lancet.Haematology 2017 ;4(4):e176-e182
Smith,S. M.; Pitcher,B. N.; Jung,S. H.; Bartlett,N. L.; Wagner-Johnston,N.; Park,S. I.; Richards,K. L.; Cashen,A. F.; Jaslowski,A.; Smith,S. E.; Cheson,B. D.; Hsi,E.; Leonard,J. P.Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials The Lancet.Haematology 2017 ;4(4):e176-e182
Landsburg,D. J.; Falkiewicz,M. K.; Petrich,A. M.; Chu,B. A.; Behdad,A.; Li,S.; Medeiros,L. J.; Cassaday,R. D.; Reddy,N. M.; Bast,M. A.; Vose,J. M.; Kruczek,K. R.; Smith,S. E.; Patel,P.; Hernandez-Ilizaliturri,F.; Karmali,R.; Rajguru,S.; Yang,D. T.; Maly,J. J.; Blum,K. A.; Zhao,W.; Vanslambrouck,C.; Nabhan,C.Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable British journal of haematology 2016 ; :
Chen,R.; Gopal,A. K.; Smith,S. E.; Ansell,S. M.; Rosenblatt,J. D.; Savage,K. J.; Connors,J. M.; Engert,A.; Larsen,E. K.; Huebner,D.; Fong,A.; Younes,A.Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma Blood 2016 ; :
Rodriguez,T. E.; Hari,P.; Stiff,P. J.; Smith,S. E.; Sterrenberg,D.; Vesole,D. V.Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2016 ; :
Ujjani,C. S.; Jung,S. H.; Pitcher,B.; Martin,P.; Park,S. I.; Blum,K. A.; Smith,S. M.; Czuczman,M.; Davids,M. S.; Levine,E.; Lewis,L. D.; Smith,S. E.; Bartlett,N. L.; Leonard,J. P.; Cheson,B. D.Phase I trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103 Blood 2016 ; :
Ujjani,C. S.; Jung,S. H.; Pitcher,B.; Martin,P.; Park,S. I.; Blum,K. A.; Smith,S. M.; Czuczman,M.; Davids,M. S.; Levine,E.; Lewis,L. D.; Smith,S. E.; Bartlett,N. L.; Leonard,J. P.; Cheson,B. D.Phase I trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103 Blood 2016 ; :
Papadopoulos,K. P.; Lopez-Jimenez,J.; Smith,S. E.; Steinberg,J.; Keating,A.; Sasse,C.; Jie,F.; Thyss,A.A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphoma Leukemia & lymphoma 2016 ; :1-8
Sobol,U.; Go,A.; Kliethermes,S.; Bufalino,S.; Rodriguez,T.; Smith,S.; Parthasarathy,M.; Stiff,P.A prospective investigation of cell dose in single-unit umbilical cord blood transplantation for adults with high-risk hematologic malignancies Bone marrow transplantation 2015 ;50(12):1519-1525
Forero-Torres,A.; Bartlett,N. L.; Berryman,R. B.; Chen,R.; Matous,J. V.; Fanale,M. A.; O'Connor,O. A.; Olshefski,R.; Smith,S. E.; Huebner,D.; Levine,P. L.; Grove,L. E.; Gopal,A. K.Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies Leukemia & lymphoma 2015 ;56(4):1151-1153
Gopal,A. K.; Chen,R.; Smith,S. E.; Ansell,S. M.; Rosenblatt,J. D.; Savage,K. J.; Connors,J. M.; Engert,A.; Larsen,E. K.; Chi,X.; Sievers,E. L.; Younes,A.Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma Blood 2014 ; :
Petrich,A. M.; Gandhi,M.; Jovanovic,B.; Castillo,J. J.; Rajguru,S.; Yang,D. T.; Shah,K. A.; Whyman,J. D.; Lansigan,F.; Hernandez-Ilizaliturri,F. J.; Lee,L. X.; Barta,S. K.; Melinamani,S.; Karmali,R.; Adeimy,C.; Smith,S.; Dalal,N.; Nabhan,C.; Peace,D.; Vose,J.; Evens,A. M.; Shah,N.; Fenske,T. S.; Zelenetz,A. D.; Landsburg,D. J.; Howlett,C.; Mato,A.; Jaglal,M.; Chavez,J. C.; Tsai,J. P.; Reddy,N.; Li,S.; Handler,C.; Flowers,C. R.; Cohen,J. B.; Blum,K. A.; Song,K.; Sun,H. L.; Press,O.; Cassaday,R.; Jaso,J.; Medeiros,L. J.; Sohani,A. R.; Abramson,J. S.Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis Blood 2014 ;124(15):2354-2361
Gopal,A. K.; Bartlett,N. L.; Forero-Torres,A.; Younes,A.; Chen,R.; Friedberg,J. W.; Matous,J. V.; Shustov,A. R.; Smith,S. E.; Zain,J.; O'Meara,M. M.; Fanale,M. A.Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy Leukemia & lymphoma 2014 ;55(10):2328-2334
Bartlett,N. L.; Chen,R.; Fanale,M. A.; Brice,P.; Gopal,A.; Smith,S. E.; Advani,R.; Matous,J. V.; Ramchandren,R.; Rosenblatt,J. D.; Huebner,D.; Levine,P.; Grove,L.; Forero-Torres,A.Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies Journal of hematology & oncology 2014 ;7:24-8722-7-24
Sobol,U.; Rodriguez,T.; Smith,S.; Go,A.; Vimr,R.; Parthasarathy,M.; Guo,R.; Stiff,P.Seven-year follow-up of allogeneic transplant using BCNU, etoposide, cytarabine and melphalan chemotherapy in patients with Hodgkin lymphoma after autograft failure: importance of minimal residual disease Leukemia & lymphoma 2014 ;55(6):1281-1287
Jain,N.; Curran,E.; Iyengar,N. M.; Diaz-Flores,E.; Kunnavakkam,R.; Popplewell,L.; Kirschbaum,M. H.; Karrison,T.; Erba,H. P.; Green,M.; Poire,X.; Koval,G.; Shannon,K.; Reddy,P. L.; Joseph,L.; Atallah,E. L.; Dy,P.; Thomas,S. P.; Smith,S. E.; Doyle,L. A.; Stadler,W. M.; Larson,R. A.; Stock,W.; Odenike,O.Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial Clinical cancer research : an official journal of the American Association for Cancer Research 2014 ;20(2):490-498
Han,T. H.; Chen,R.; Advani,R.; Berryman,R. B.; Smith,S. E.; Forero-Torres,A.; Rosenblatt,J. D.; Smith,M. R.; Zain,J.; Hunder,N. N.; Engert,A.Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies CANCER CHEMOTHERAPY AND PHARMACOLOGY 2013 ;72(1):241-249
Stiff,P. J.; Fox-Geiman,M. P.; Kiley,K.; Rychlik,K.; Parthasarathy,M.; Fletcher-Gonzalez,D.; Porter,N.; Go,A.; Smith,S. E.; Rodriguez,T. E.Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2013 ;19(1):49-55.e1
O'Brien,S.; Schiller,G.; Lister,J.; Damon,L.; Goldberg,S.; Aulitzky,W.; Ben-Yehuda,D.; Stock,W.; Coutre,S.; Douer,D.; Heffner,L. T.; Larson,M.; Seiter,K.; Smith,S.; Assouline,S.; Kuriakose,P.; Maness,L.; Nagler,A.; Rowe,J.; Schaich,M.; Shpilberg,O.; Yee,K.; Schmieder,G.; Silverman,J. A.; Thomas,D.; Deitcher,S. R.; Kantarjian,H.High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013 ;31(6):676-683
Nabhan,C.; Smith,S. M.; Helenowski,I.; Ramsdale,E.; Parsons,B.; Karmali,R.; Feliciano,J.; Hanson,B.; Smith,S.; McKoy,J.; Larsen,A.; Hantel,A.; Gregory,S.; Evens,A. M.Analysis of very elderly (>/=80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome British journal of haematology 2012 ;156(2):196-204
Nabhan,C.; Smith,S. M.; Helenowski,I.; Ramsdale,E.; Parsons,B.; Karmali,R.; Feliciano,J.; Hanson,B.; Smith,S.; McKoy,J.; Larsen,A.; Hantel,A.; Gregory,S.; Evens,A. M.Analysis of very elderly (>/=80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome British journal of haematology 2012 ;156(2):196-204
Gopal,A. K.; Ramchandren,R.; O'Connor,O. A.; Berryman,R. B.; Advani,R. H.; Chen,R.; Smith,S. E.; Cooper,M.; Rothe,A.; Matous,J. V.; Grove,L. E.; Zain,J.Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation Blood 2012 ;120(3):560-568
Choi,S. W.; Stiff,P.; Cooke,K.; Ferrara,J. L.; Braun,T.; Kitko,C.; Reddy,P.; Yanik,G.; Mineishi,S.; Paczesny,S.; Hanauer,D.; Pawarode,A.; Peres,E.; Rodriguez,T.; Smith,S.; Levine,J. E.TNF-inhibition with etanercept for graft-versus-host disease prevention in high-risk HCT: lower TNFR1 levels correlate with better outcomes Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2012 ;18(10):1525-1532
Raza,A.; Galili,N.; Mulford,D.; Smith,S. E.; Brown,G. L.; Steensma,D. P.; Lyons,R. M.; Boccia,R.; Sekeres,M. A.; Garcia-Manero,G.; Mesa,R. A.Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS) Journal of hematology & oncology 2012 ;5:18-8722-5-18
Raza,A.; Galili,N.; Smith,S. E.; Godwin,J.; Boccia,R. V.; Myint,H.; Mahadevan,D.; Mulford,D.; Rarick,M.; Brown,G. L.; Schaar,D.; Faderl,S.; Komrokji,R. S.; List,A. F.; Sekeres,M.A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome Cancer 2012 ;118(8):2138-2147
Younes,A.; Gopal,A. K.; Smith,S. E.; Ansell,S. M.; Rosenblatt,J. D.; Savage,K. J.; Ramchandren,R.; Bartlett,N. L.; Cheson,B. D.; de Vos,S.; Forero-Torres,A.; Moskowitz,C. H.; Connors,J. M.; Engert,A.; Larsen,E. K.; Kennedy,D. A.; Sievers,E. L.; Chen,R.Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012 ;30(18):2183-2189
Evens,A. M.; Helenowski,I.; Ramsdale,E.; Nabhan,C.; Karmali,R.; Hanson,B.; Parsons,B.; Smith,S.; Larsen,A.; McKoy,J. M.; Jovanovic,B.; Gregory,S.; Gordon,L. I.; Smith,S. M.A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era Blood 2012 ;119(3):692-695
Evens,A. M.; Helenowski,I.; Ramsdale,E.; Nabhan,C.; Karmali,R.; Hanson,B.; Parsons,B.; Smith,S.; Larsen,A.; McKoy,J. M.; Jovanovic,B.; Gregory,S.; Gordon,L. I.; Smith,S. M.A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era Blood 2012 ;119(3):692-695
Evens,A. M.; David,K. A.; Helenowski,I.; Nelson,B.; Kaufman,D.; Kircher,S. M.; Gimelfarb,A.; Hattersley,E.; Mauro,L. A.; Jovanovic,B.; Chadburn,A.; Stiff,P.; Winter,J. N.; Mehta,J.; Van Besien,K.; Gregory,S.; Gordon,L. I.; Shammo,J. M.; Smith,S. E.; Smith,S. M.Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 ;28(6):1038-1046
Evens,A. M.; David,K. A.; Helenowski,I.; Nelson,B.; Kaufman,D.; Kircher,S. M.; Gimelfarb,A.; Hattersley,E.; Mauro,L. A.; Jovanovic,B.; Chadburn,A.; Stiff,P.; Winter,J. N.; Mehta,J.; Van Besien,K.; Gregory,S.; Gordon,L. I.; Shammo,J. M.; Smith,S. E.; Smith,S. M.Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 ;28(6):1038-1046
Smith,S. M.; van Besien,K.; Karrison,T.; Dancey,J.; McLaughlin,P.; Younes,A.; Smith,S.; Stiff,P.; Lester,E.; Modi,S.; Doyle,L. A.; Vokes,E. E.; Pro,B.Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 ;28(31):4740-4746
Smith,S. M.; van Besien,K.; Karrison,T.; Dancey,J.; McLaughlin,P.; Younes,A.; Smith,S.; Stiff,P.; Lester,E.; Modi,S.; Doyle,L. A.; Vokes,E. E.; Pro,B.Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 ;28(31):4740-4746
Mumby,P. B.; Garcia,C.; Trivedi-Purohit,R.; Gourvitz,R.; Rychlik,K.; Rodriguez,T.; Smith,S. E.; Toor,A. A.; Rao,M.; Stiff,P. J.The impact of pharmacotherapy on depression and quality of life in patients undergoing a bone marrow transplant (BMT). ASCO Meeting Abstracts 2010 ;28(15_suppl):9132
Raza,A.; Galili,N.; Smith,S.; Godwin,J.; Lancet,J.; Melchert,M.; Jones,M.; Keck,J. G.; Meng,L.; Brown,G. L.; List,A.Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome Blood 2009 ;113(26):6533-6540
Toor,A.; Rodriguez,T.; Bauml,M.; Mathews,H.; Shanti,S.; Senitzer,D.; Kini,A.; Norton,J.; Parthasarathy,M.; Mohideen,N.; Petrowsky,C.; Bonilla,B.; Smith,S.; Stiff,P.Feasibility of conditioning with thymoglobulin and reduced intensity TBI to reduce acute GVHD in recipients of allogeneic SCT Bone marrow transplantation 2008 ;42(11):723-731
Nand,S.; Godwin,J.; Smith,S.; Barton,K.; Michaelis,L.; Alkan,S.; Veerappan,R.; Rychlik,K.; Germano,E.; Stiff,P.Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial Leukemia & lymphoma 2008 ;49(11):2141-2147
Smith,S. E.; Toor,A.; Rodriguez,T.; Stiff,P.The administration of polymerized human hemoglobin (Pyridoxylated) to a Jehovah's Witness after submyeloablative stem cell transplantation complicated by delayed graft failure Comprehensive therapy 2006 ;32(3):172-175
Farray,D.; Al-Masri,H.; Hattersley,E.; Smith,S. E.Megakaryoblastic leukemia with involvement of the pleural fluid. American Journal of Hematology 2005 ;79(3):238-239
Godwin,J. E.; Smith,S. E.Acute myeloid leukemia in the older patient Critical Reviews in Oncology-Hematology 2003 ;48(Suppl):S17-26